van Laar J M, Farge D, Tyndall A
Musculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Newcastle, UK.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii35-8. doi: 10.1136/ard.2008.098384.
High-dose immunosuppressive therapy and autologous stem cell transplantation (commonly referred to as "stem cell transplantation") is an established treatment for a variety of haemato-oncological conditions. Recent studies have confirmed its potent clinical and immunological effects in rheumatic autoimmune diseases, including severe diffuse systemic sclerosis (SSc). With modifications of treatment protocols and more stringent selection of patients, the safety profile of stem cell transplantation has improved as expressed in lower treatment-related morbidity and mortality. Prospective, randomised trials are in progress in Europe and North America to compare the safety and efficacy of stem cell transplantation with conventional chemotherapy in patients with early diffuse SSc, on the premise that induction of remission in early disease can be achieved by stem cell transplantation as a means to interrupt fibrogenesis.
大剂量免疫抑制疗法和自体干细胞移植(通常称为“干细胞移植”)是治疗多种血液肿瘤疾病的既定疗法。最近的研究证实了其在风湿性自身免疫性疾病,包括严重弥漫性系统性硬化症(SSc)中的强大临床和免疫效果。随着治疗方案的改进和对患者选择更加严格,干细胞移植的安全性有所改善,表现为与治疗相关的发病率和死亡率降低。欧洲和北美正在进行前瞻性随机试验,以比较干细胞移植与传统化疗对早期弥漫性SSc患者的安全性和有效性,前提是干细胞移植作为一种中断纤维生成的手段可以在早期疾病中诱导缓解。